<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303316</url>
  </required_header>
  <id_info>
    <org_study_id>A3L16</org_study_id>
    <nct_id>NCT00303316</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants</brief_title>
  <official_title>Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This study will assess both the antibody persistence of the investigational vaccine and the
      immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers
      who participated in an earlier study in order to determine if they are still protected before
      they receive a booster dose of D, T, IPV, pertussis or Hib vaccines and also to assess the
      quality of the induced immune memory in response to a booster dose of the same vaccine as in
      the primary series.

      Primary Objective:

      To describe the antibody persistence at 18 months of age and the booster effect of a dose of
      PENTAXIM™ on immunogenicity.

      Secondary objective:

      To describe the safety profile of the booster dose PENTAXIM™ in each vaccine group defined by
      the vaccines received during the primary series.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</measure>
    <time_frame>Day 0 (Before booster vaccination)</time_frame>
    <description>Antibody persistence (pre-booster) were defined as titers ≥ 10 mIU/mL for hepatitis B (Hep B;); ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.01 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for polio types 1, 2, and 3; and ≥ 4 EU/mL for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Booster Response in Participants at 18 Months of Age Following Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</measure>
    <time_frame>Day 30 Post-booster Vaccination</time_frame>
    <description>Booster response were defined as titers ≥ 1.0 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.1 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for Polio types 1, 2, and 3; and for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) ≥ 4 EU/mL and a ≥ 4 fold increase from pre-booster to post-booster value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antibodies Before and After Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</measure>
    <time_frame>Day 0 (pre-booster) and Day 30 post-booster</time_frame>
    <description>Antibody titers determination:
Hepatitis B (Hep B) by enhanced chemiluminescence assay; Haemophilus influenzae type b (PRP), Tetanus, Pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA); Diphtheria by neutralization test; Poliovirus types 1,2, and 3 by microneutralization assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-booster Vaccination With PENTAXIM™</measure>
    <time_frame>Day 0 up to Day 30 post-booster vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 was defined as: Pain, cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hour or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥ 3 feeds/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>DTacP IPV HepB PRP-T Combined Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PENTAXIM™ and ENGERIX B® Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV//PRP~T combined vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>DTacP IPV HepB PRP-T Combined Vaccine Group</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV//PRP~T combined vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>PENTAXIM™ and ENGERIX B® Vaccine Group</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Toddler at 18 months of age (range: 510 days to 578 days of age inclusive)

          -  Participated in study A3L02 (NCT00831311) and has completed the three-dose primary
             series with either diphtheria, tetanus, pertussis (2-component acellular), recombinant
             Hepatitis B Hansenula and poliomyelitis vaccine adsorbed, and Haemophilus influenzae
             type b vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T) or PENTAXIM™ and
             ENGERIX B® PEDIATRICO at 2, 4, and 6 months of age

          -  Written informed consent form signed by at least one parent or by a legal
             representative and an independent witness

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  Participation in another clinical trial in the four weeks preceding the trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding 6 months or long-term systemic
             corticosteroids therapy

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to a vaccine containing the same substances

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Blood or blood-derived products received in the last six months

          -  Any vaccination in the four weeks preceding the trial

          -  Vaccination with a vaccine containing diphtheria, tetanus, pertussis, Haemophilus
             influenzae type b, polio, or hepatitis B antigen, since the end of the primary series

          -  History of documented diphtheria, tetanus, pertussis, Haemophilus influenzae type b,
             polio, or hepatitis B infection(s) (confirmed either clinically, serologically, or
             microbiologically)

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination

          -  History of seizures

          -  Fever (axillary temperature ≥37.4°C or equivalent rectal temperature ≥38.0°C) or acute
             illness on the day of inclusion

          -  Known contraindication to further vaccination with a pertussis vaccine such as:

          -  Encephalopathy; Inconsolable crying for &gt;3 hours within 48 hours following vaccine
             injection

          -  Hypotonic hyporesponsive episode within 48 hours following vaccine injection

          -  Seizures with or without fever within three days following vaccine injection

          -  Axillary temperature &gt;39.4°C or equivalent rectal temperature &gt; 40.0°C within 48 hours
             following vaccine injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>510 Days</minimum_age>
    <maximum_age>578 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <state>Provincia de Córdoba</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <results_reference>
    <citation>Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012 Jan;31(1):e24-30. doi: 10.1097/INF.0b013e318242460a.</citation>
    <PMID>22157567</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2006</study_first_posted>
  <results_first_submitted>December 11, 2012</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>whooping cough</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 15 February 2006 to 03 October 2006 at 1 clinical center in Argentina.</recruitment_details>
      <pre_assignment_details>A total of 458 participants who met all the inclusion and none of the exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTacP-IPV-Hep B-PRP~T Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
        <group group_id="P2">
          <title>PENTAXIM™ and ENGERIX B® Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTacP-IPV-Hep B-PRP~T Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
        <group group_id="B2">
          <title>PENTAXIM™ and ENGERIX B® Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="0.436"/>
                    <measurement group_id="B2" value="17.7" spread="0.492"/>
                    <measurement group_id="B3" value="17.6" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
        <description>Antibody persistence (pre-booster) were defined as titers ≥ 10 mIU/mL for hepatitis B (Hep B;); ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.01 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for polio types 1, 2, and 3; and ≥ 4 EU/mL for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA).</description>
        <time_frame>Day 0 (Before booster vaccination)</time_frame>
        <population>Antibody Persistence was assessed in all enrolled participants with pre-booster vaccination data (Intent-to-Treat population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTacP-IPV-Hep B-PRP~T Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
          <group group_id="O2">
            <title>PENTAXIM™ and ENGERIX B® Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
          <description>Antibody persistence (pre-booster) were defined as titers ≥ 10 mIU/mL for hepatitis B (Hep B;); ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.01 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for polio types 1, 2, and 3; and ≥ 4 EU/mL for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA).</description>
          <population>Antibody Persistence was assessed in all enrolled participants with pre-booster vaccination data (Intent-to-Treat population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hepatitis B (N = 228, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (N = 224, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (N = 228, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (N = 229, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 (N = 214, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N = 217, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N = 214, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertussis Toxoid (N= 216, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Filamentous Hemagglutinin (N = 230, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Booster Response in Participants at 18 Months of Age Following Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
        <description>Booster response were defined as titers ≥ 1.0 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.1 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for Polio types 1, 2, and 3; and for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) ≥ 4 EU/mL and a ≥ 4 fold increase from pre-booster to post-booster value.</description>
        <time_frame>Day 30 Post-booster Vaccination</time_frame>
        <population>Booster responses were assessed in all vaccinated participants with endpoint data following the booster vaccination (Intent-to-Treat population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTacP-IPV-Hep B-PRP~T Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
          <group group_id="O2">
            <title>PENTAXIM™ and ENGERIX B® Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Booster Response in Participants at 18 Months of Age Following Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
          <description>Booster response were defined as titers ≥ 1.0 µg/mL for Haemophilus influenzae type b (PRP); ≥ 0.1 IU/mL for Diphtheria and Tetanus; ≥ 8 (1/dil) for Polio types 1, 2, and 3; and for Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) ≥ 4 EU/mL and a ≥ 4 fold increase from pre-booster to post-booster value.</description>
          <population>Booster responses were assessed in all vaccinated participants with endpoint data following the booster vaccination (Intent-to-Treat population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP (N = 223, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (N = 225, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (N = 222, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 (N = 211, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N = 208, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N = 205, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertussis Toxoid (N = 226, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertussis Toxoid (4-Fold Rise: N = 211, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Filamentous Hemagglutinin (N = 227, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (4-Fold Rise: N = 225, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-booster Vaccination With PENTAXIM™</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 was defined as: Pain, cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hour or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥ 3 feeds/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
        <time_frame>Day 0 up to Day 30 post-booster vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in the enrolled and vaccinated participants, Safety Analysis Set population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTacP-IPV-Hep B-PRP~T Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
          <group group_id="O2">
            <title>PENTAXIM™ and ENGERIX B® Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-booster Vaccination With PENTAXIM™</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 was defined as: Pain, cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hour or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥ 3 feeds/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
          <population>Solicited injection site and systemic reactions were assessed in the enrolled and vaccinated participants, Safety Analysis Set population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Antibodies Before and After Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
        <description>Antibody titers determination:
Hepatitis B (Hep B) by enhanced chemiluminescence assay; Haemophilus influenzae type b (PRP), Tetanus, Pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA); Diphtheria by neutralization test; Poliovirus types 1,2, and 3 by microneutralization assay.</description>
        <time_frame>Day 0 (pre-booster) and Day 30 post-booster</time_frame>
        <population>Geometric mean titers were assessed in all participants with endpoint data who received the booster vaccine (Intent-to-Treat Analysis Set for immunogenicity).</population>
        <group_list>
          <group group_id="O1">
            <title>DTacP-IPV-Hep B-PRP~T Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
          <group group_id="O2">
            <title>PENTAXIM™ and ENGERIX B® Group</title>
            <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Antibodies Before and After Booster Vaccination With PENTAXIM™ Following a Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.</title>
          <description>Antibody titers determination:
Hepatitis B (Hep B) by enhanced chemiluminescence assay; Haemophilus influenzae type b (PRP), Tetanus, Pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA); Diphtheria by neutralization test; Poliovirus types 1,2, and 3 by microneutralization assay.</description>
          <population>Geometric mean titers were assessed in all participants with endpoint data who received the booster vaccine (Intent-to-Treat Analysis Set for immunogenicity).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hepatitis B Pre-booster (N = 228, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" lower_limit="69.2" upper_limit="111"/>
                    <measurement group_id="O2" value="197" lower_limit="168" upper_limit="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Pre-booster (N = 224, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.399" lower_limit="0.327" upper_limit="0.487"/>
                    <measurement group_id="O2" value="0.326" lower_limit="0.270" upper_limit="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Post-booster (N = 223, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="23.0" upper_limit="32.7"/>
                    <measurement group_id="O2" value="41.4" lower_limit="35.0" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Pre-booster (N = 228, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" lower_limit="0.018" upper_limit="0.027"/>
                    <measurement group_id="O2" value="0.018" lower_limit="0.015" upper_limit="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Post-booster (N = 225, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.58" upper_limit="2.32"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.74" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Pre-booster (N = 229, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.287" lower_limit="0.255" upper_limit="0.325"/>
                    <measurement group_id="O2" value="0.171" lower_limit="0.153" upper_limit="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Post-booster (N = 222, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="4.37" upper_limit="5.31"/>
                    <measurement group_id="O2" value="4.54" lower_limit="4.07" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Pre-booster (N= 214, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303" lower_limit="251" upper_limit="365"/>
                    <measurement group_id="O2" value="232" lower_limit="193" upper_limit="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Post-booster (N = 211, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7243" lower_limit="6218" upper_limit="8436"/>
                    <measurement group_id="O2" value="9996" lower_limit="8521" upper_limit="11725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Pre-booster (N = 217, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" lower_limit="300" upper_limit="457"/>
                    <measurement group_id="O2" value="292" lower_limit="234" upper_limit="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Post-booster (N = 208, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8512" lower_limit="7281" upper_limit="9952"/>
                    <measurement group_id="O2" value="11229" lower_limit="9574" upper_limit="13170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Pre-booster (N = 214, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257" lower_limit="202" upper_limit="327"/>
                    <measurement group_id="O2" value="223" lower_limit="174" upper_limit="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Post-booster (N = 205, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10975" lower_limit="9066" upper_limit="13286"/>
                    <measurement group_id="O2" value="14482" lower_limit="12067" upper_limit="17380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Pre-booster (N = 216, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="9.37" upper_limit="12.3"/>
                    <measurement group_id="O2" value="12.9" lower_limit="11.3" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Post-booster (N = 226, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" lower_limit="205" upper_limit="249"/>
                    <measurement group_id="O2" value="325" lower_limit="292" upper_limit="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Pre-booster (N = 230, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="24.5" upper_limit="32.5"/>
                    <measurement group_id="O2" value="19.0" lower_limit="16.7" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Post-booster (N = 227, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335" lower_limit="305" upper_limit="368"/>
                    <measurement group_id="O2" value="333" lower_limit="305" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 (before booster vaccination) up to Day 30 post-booster vaccination in the Safety Analysis Set population.</time_frame>
      <desc>The Safety Analysis Set (SafAS) was defined as the set of participants who received the booster vaccine. The analysis was based upon the number of participants for whom each safety assessment was performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTacP-IPV-Hep B-PRP~T Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of Diphtheria (D), Tetanus (T), Pertussis (acellular component [aP]), hepatitis B (Hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-HepB-PRP~T), (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
        <group group_id="E2">
          <title>PENTAXIM™ and ENGERIX B® Group</title>
          <description>Participants received a booster dose of PENTAXIM™ at 18 months of age in this study. They had received 3 primary-series doses of PENTAXIM™ and ENGERIX B® PEDIATRICO (1 dose each at 2, 4, and 6 months of age) in Study A3L02 (NCT00831311).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="231"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Injection Site Erythema</sub_title>
                <counts group_id="E1" events="66" subjects_affected="66" subjects_at_risk="231"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Pain</sub_title>
                <counts group_id="E1" events="112" subjects_affected="112" subjects_at_risk="231"/>
                <counts group_id="E2" events="117" subjects_affected="117" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Swelling</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="231"/>
                <counts group_id="E2" events="89" subjects_affected="89" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="85" subjects_affected="85" subjects_at_risk="231"/>
                <counts group_id="E2" events="78" subjects_affected="78" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="231"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="231"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="231"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="231"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="231"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

